Ophthalmic Delivery

Drops, ointments, gels, contact-lens-integrated, ocular inserts, intraocular implants, and intravitreal depot formats for ophthalmic bioregulator delivery.

Full mechanistic definition forthcoming.

A documented format in pharmaceutical practice.

Historical timeline of the delivery format in the pharmaceutical literature — first characterization, commercial precedents, decades of regulatory-approved use — forthcoming.

How the format delivers.

Absorption pathway, bioavailability characteristics, first-pass metabolism considerations, onset and duration profiles — forthcoming.

Bioregulators formulated for this platform.

Tetrapeptide-AEDG (retinal applications) and selected bioregulators formulated for ophthalmic delivery.

See the full bioregulator class and the per-compound published literature for compound-specific research references.

Classification and oversight.

503A compounding, NDA pathways, and hospital-administered ophthalmic preparations.

Detailed regulatory analysis — agency-specific requirements, classification thresholds, and pathway-specific labeling considerations — forthcoming.

The format in the scientific literature.

PubMed-indexed peer-reviewed references establishing the format as legitimate pharmaceutical science — forthcoming.

The Atumnus Ocugenix™ platform.

The Ocugenix™ platform is the Atumnus patent-pending embodiment of Ophthalmic Delivery. It is licensed to operating affiliates for commercial development across the Opticeutical and Endoceutical tiers, and is one of the branded delivery technologies that anchors the Atumnus intellectual-property estate.

The Ocugenix™ trademark and associated patent-pending technology are held by Atumnus LLC, the founding entity of endogenic pharmacology. See affiliated entities for institutional structure.

Adjacent delivery formats.

Within the same cluster (Parenteral, Surgical, and Implantable Delivery), see the full set of delivery platforms in this category.

← Back to all delivery platforms